(Q34294358)

1 August 2017

1 reference

title

Position statement: global neuraminidase inhibitor susceptibility network (English)

1 reference

1 August 2017

M Zambon

1

1 reference

PubMed ID

11428241

1 August 2017

F G Hayden

series ordinal

2

1 reference

PubMed ID

11428241

1 August 2017

Global Neuraminidase Inhibitor Susceptibility Network

series ordinal

3

1 reference

1 August 2017

1 March 2001

1 reference

1 August 2017

1 reference

1 August 2017

49

1 reference

1 August 2017

3

1 reference

1 August 2017

147-156

1 reference

In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Influenza virus neuraminidase: structure, antibodies, and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Influenza virus neuraminidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Emergence and apparent transmission of rimantadine-resistant influenza A virus in families

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2).

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Resistance of influenza viruses to neuraminidase inhibitors--a review.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Influenza virus resistance to neuraminidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

Low incidence of rimantadine resistance in field isolates of influenza A viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900124-3

7 January 2021

10.1016/S0166-3542(01)00124-3

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11428241